Patents Assigned to Hadasit Medical Research Services
  • Compositions and methods for treatment of hematological malignancies
    Patent number: 10000549
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: June 19, 2018
    Assignees: KAHR Medical Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventor: Michal Dranitzki Elhalel
  • Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
    Patent number: 9993497
    Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
    Type: Grant
    Filed: December 30, 2013
    Date of Patent: June 12, 2018
    Assignees: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar Cohen, Yaron Ilan, Eyal Shteyer, Ami Ben-Ya'acov
  • Combination therapy of beta-glycolipids and antibodies for the treatment of immune-related disorders
    Patent number: 9981037
    Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, ?-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with ?-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 29, 2018
    Assignees: The Brigham and Women's Hospital, Inc., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron Ilan, Howard L. Weiner
  • PAR1 AND PAR2 C-TAIL PEPTIDES AND PEPTIDE MIMETICS
    Publication number: 20180134752
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Application
    Filed: August 21, 2017
    Publication date: May 17, 2018
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel BAR-SHAVIT
  • Regeneration and repair of mesenchymal tissue using amelogenin
    Patent number: 9957314
    Abstract: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: May 1, 2018
    Assignees: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Dan Deutsch, Amir Haze, Anat Blumenfeld
  • INHIBITORS OF NEUROLIGIN 4 - NEUREXIN 1-BETA PROTEIN-PROTEIN INTERACTION FOR TREATMENT OF LIVER DISORDERS
    Publication number: 20180111989
    Abstract: Provided is a method for treating, attenuating and/or preventing progression of a liver disorder in a subject, the method including administering a therapeutically effective amount of an agent capable of interfering with, inhibiting and/or preventing neuroligin 4 (NLGn4)-Neurexin 1-beta (Nrx1b) protein-protein interaction. Also provided are compositions including the agent.
    Type: Application
    Filed: March 31, 2016
    Publication date: April 26, 2018
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventor: Rifaat SAFADI
  • Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
    Patent number: 9944988
    Abstract: The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an NLGn4 gene product in the immune cell population using NLGn4 specific primers or NLGn4 specific probes.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: April 17, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rifaat Safadi
  • USE OF ALGINATE COMPOSITIONS IN PREVENTING OR REDUCING LIVER DAMAGE CAUSED BY A HEPATOTOXIC AGENT
    Publication number: 20180099006
    Abstract: Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent.
    Type: Application
    Filed: December 11, 2017
    Publication date: April 12, 2018
    Applicants: Hadasit Medical Research Services and Development Ltd., B.G. Negev Technologies & Applications Ltd., at Ben-Gurion University
    Inventors: Smadar COHEN, Yaron ILAN, Eyal SHTEYER, Ami BEN-YA'ACOV
  • NITROXIDE RADICALS FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT
    Publication number: 20180085347
    Abstract: Cyclic nitroxide compounds including, but not limited to, compounds having the general formula I: wherein the dashed line and R1-R8 are as defined herein, are disclosed herein for use in treating diseases and disorders of the respiratory tract and/or respiratory tract remodeling.
    Type: Application
    Filed: March 24, 2016
    Publication date: March 29, 2018
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.
    Inventors: Sara GOLDSTEIN, Amram SAMUNI, Neville BERKMAN
  • Low friction coatings for use in dental and medical devices
    Patent number: 9877806
    Abstract: The present invention provides an article, at least part of it being coated by inorganic fullerene-like (IF) nanoparticles or composite containing such nanoparticles. Preferably, the invention provides an article made of metal, for use in dentistry or medicine e.g. archwire, needle or catheter, having a friction-reducing film, and methods for coating such articles with a friction-reducing film.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: January 30, 2018
    Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., HADASIT MEDICAL RESEARCH SERVICE AND DEVELOPMENT LTD., HOLON ACADEMIC INSTITUTE OF TECHNOLOGY
    Inventors: Reshef Tenne, Alon Katz, Meir Redlich, Lev Rapoport
  • Human stem cell-derived neural precursors for treatment of autoimmune diseases of the central nervous system
    Patent number: 9862925
    Abstract: The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: January 9, 2018
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventors: Michal Aharonowiz, Ofira Einstein, Benjamin Reubinoff, Tamir Ben-Hur
  • Composition for use in detection of sFlt-14
    Patent number: 9797911
    Abstract: An isolated polypeptide comprising an amino acid sequence at least 70% homologous to SEQ ID NO: 4 and an isolated polynucleotide encoding same are disclosed. A polynucleotide comprising a nucleic acid sequence capable of specifically hybridizing to the isolated polynucleotide and an isolated antibody comprising an antigen recognition domain which specifically binds the isolated polypeptide are also disclosed. Pharmaceutical compositions, methods of diagnosing and treating comprising same are also disclosed.
    Type: Grant
    Filed: June 15, 2014
    Date of Patent: October 24, 2017
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Eli Keshet, Shay Sela, Ahuva Itin, Simcha Yagel
  • PAR1 and PAR2 c-tail peptides and peptide mimetics
    Patent number: 9745347
    Abstract: The present invention concerns isolated PAR1 cytoplasmic tail (c-tail) peptides and isolated PAR2 cytoplasmic tail (c-tail) peptides, as well as compositions comprising these peptides, uses thereof and methods of treating various diseases, in particular cancer.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: August 29, 2017
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventor: Rachel Bar-Shavit
  • METHODS OF SELECTING RETINAL PIGMENTED EPITHELIAL CELLS
    Publication number: 20170199190
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Application
    Filed: March 28, 2017
    Publication date: July 13, 2017
    Applicants: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan REUBINOFF, Nurit YACHIMOVICH-COHEN, Limor MATZRAFI
  • Tissue regeneration membrane
    Patent number: 9669136
    Abstract: The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: June 6, 2017
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Michael Friedman, Yoel Sasson, Ada Grin, Rami Mosheiff, Jacob Rachmilewitz
  • Methods of selecting retinal pigmented epithelial cells
    Patent number: 9658216
    Abstract: A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises: (a) analyzing the cells of the mixed population of cells for at least one of the following parameters: (i) cells which autofluorescence above a predetermined threshold; (ii) cells which express CD81 above a predetermined threshold; and (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: May 23, 2017
    Assignees: Cell Cure Neurosciences Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Benjamin Eithan Reubinoff, Nurit Yachimovich-Cohen, Limor Matzrafi
  • TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS WITH DELAYED-RELEASE 6-MERCAPTOPURINE
    Publication number: 20170105996
    Abstract: Methods of treating patients suffering from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), including those also suffering front type II diabetes mellitus (T2DM), with a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 20, 2017
    Applicants: Teva Pharmaceutical Industries, Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Yaron ILAN, Doina Cosma ROMAN, Michael HAYDEN, Einat AMIT-ROMACH
  • Methods and compositions for treating viral infections
    Patent number: 9616067
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: April 11, 2017
    Assignees: Hadasit Medical Research Services and Development Ltd., The Hong Kong University of Science and Technology
    Inventors: Richard K. Haynes, Dana G. Wolf
  • SAFE DEVICE FOR IONTOPHORETIC DELIVERY OF DRUGS
    Publication number: 20170080220
    Abstract: Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.
    Type: Application
    Filed: November 29, 2016
    Publication date: March 23, 2017
    Applicants: Hadasit Medical Research Services & Development Li mited, Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Abraham J. DOMB, Joseph FRUCHT-PERY, Mervyn SHAPIRO
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
    Publication number: 20170071952
    Abstract: The present invention provides compositions and methods for treating, preventing, and inhibiting viral replication, viral infections and viral diseases and disorders, comprising the use of artemisinin derivatives having anti-viral activity.
    Type: Application
    Filed: November 25, 2016
    Publication date: March 16, 2017
    Applicants: THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY, HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Richard K. HAYNES, Dana G. WOLF